Perfusion Medical was recently awarded a $1.8 million grant to support the delivery of an initial Human Clinical Trial for its lead candidate. PM-208 is a novel IV therapeutic designed to treat hemorrhagic shock and other ischemic conditions by rapidly reestablishing blood flow through tissue capillaries, resolving ischemia, and protecting vital organs.

Since its inception in 2020, Perfusion Medical has received $7.25 million in grant funding from the Defense Health Agency (DHA), U.S. Air Force (AFWERX), and National Institutes of Health (NIH). This latest award marks a significant milestone in the development of a drug that is poised to be a game-changer in acute cardiovascular medicine.